Tedizolid Side Effects
Tedizolid is generally well-tolerated with a favorable safety profile, particularly for short-course therapy (6 days), but prolonged use carries risks of peripheral neuropathy, optic neuropathy, bone marrow suppression, and potential serotonin syndrome when combined with serotonergic medications.
Common Side Effects (Short-Course Therapy)
Based on FDA labeling and clinical trials, tedizolid demonstrates lower rates of adverse effects compared to linezolid 1, 2:
Gastrointestinal Effects
- Significantly fewer GI side effects than linezolid (RR 0.69; 95% CI 0.57-0.85) 2
- Nausea, vomiting, and diarrhea occur but are less frequent than with other oxazolidinones 2
Hematologic Effects
- Lower risk of thrombocytopenia (RR 0.60; 95% CI 0.41-0.88) compared to linezolid 2
- Lower risk of neutropenia (RR 0.35; 95% CI 0.18-0.69) compared to linezolid 2
- Post-marketing surveillance confirms hematologic toxicities remain a class effect but occur less frequently 3
Serious Adverse Effects (Prolonged Therapy)
Peripheral Neuropathy
This is the most concerning adverse effect with extended tedizolid use 4, 5, 6:
- Appears after median 12.4 months of continuous therapy 5
- Presents as paresthesias, dysesthesias, or worsening of pre-existing neuropathy 5
- Axonal sensory polyneuropathy confirmed on electromyoneurography 5
- Risk factors include: diabetes, renal impairment, prior linezolid exposure 5
- Partial reversibility: 3 of 5 patients showed clinical recovery after discontinuation, but diabetic patients had persistent symptoms 5
Optic Neuropathy
- Rare with short courses (no cases in RCTs) 6
- 2 cases reported in 87 patients receiving prolonged therapy in prospective studies 6
- Time and dose-dependent, similar to linezolid 6
Bone Marrow Suppression
From animal toxicology studies 1:
- Dose and time-dependent bone marrow hypocellularity affecting myeloid, erythroid, and megakaryocyte lines
- Reduction in RBCs, WBCs, and platelets
- Occurs at exposures ≥6-fold greater than therapeutic doses
- Reversible upon discontinuation 1
Immunosuppression
- Reduced splenic B and T cells in animal studies 1
- Reduced plasma IgG titers at exposures ≥3-fold therapeutic levels 1
Emerging Safety Signals (Post-Marketing)
Post-marketing surveillance identified potential new signals 3:
- Hepatic cytolysis and elevated gamma-glutamyltransferase
- Mental status changes
- Tooth discoloration
- Melena (GI bleeding)
- Median onset: 3 days, with nearly one-third occurring on Day 0 3
Drug Interactions and Special Risks
Serotonin Syndrome
Tedizolid is a weak, nonselective, reversible monoamine oxidase inhibitor 7:
- Risk of serotonin syndrome when combined with SSRIs or other serotonergic agents 7
- One case report of hypertensive crisis in a patient on antidepressants, possibly representing serotonin toxicity 8
- Avoid concomitant use with serotonergic medications when possible 8
Monitoring Recommendations
For Short-Course Therapy (≤6 days)
- Minimal monitoring required - excellent safety profile 1, 2
- Baseline CBC if patient has risk factors for cytopenias
For Prolonged Therapy (>2 weeks)
Implement comprehensive monitoring 4, 5, 6:
- Weekly CBC for first month, then every 2 weeks
- Monthly neurologic assessment: screen for paresthesias, dysesthesias, visual changes
- Baseline and periodic liver function tests (given emerging hepatic signals) 3
- Electromyoneurography if neuropathic symptoms develop 5
- Ophthalmologic examination if visual symptoms occur 6
- Consider therapeutic drug monitoring in high-risk patients 4
Clinical Pitfalls
Do not assume tedizolid is completely free of oxazolidinone class toxicities - neuropathy and myelosuppression still occur with prolonged use 4, 5
Diabetic patients are at higher risk for persistent neuropathy - use with extreme caution in this population for prolonged courses 5
Prior linezolid toxicity does not preclude tedizolid neuropathy - 4 of 5 neuropathy cases had switched from linezolid, including one for neuropathy 5
Screen medication lists for serotonergic agents before prescribing - risk of dangerous interactions 8
Neuropathy may not be fully reversible - particularly in patients with underlying risk factors 5